**INTRODUCTION**

Dystrophin loss leads to the progressive muscle-wasting disease DMD (Duchenne muscular dystrophy). Following the identification of the DMD gene by Kunkel and co-workers [1] by positional cloning in the late 1980s, it was realized that the protein product dystrophin was a large cytoskeletal protein with homology to the spectrin family of proteins [2–4]. Like spectrin and α-actinin, dystrophin and utrophin can provide a link between the F-actin (filamentous actin) cytoskeleton and transmembrane protein dystroglycan through the actin-binding domain, and the link between cysteine-rich region and dystroglycan are crucial to dystrophin function. The spectrin repeats are to a large extent redundant, and only mild phenotypes are associated with loss of the C-terminal coiled-coil repeats. Within the cysteine-rich region, arguably the most important region of dystrophin, are three distinct domains that contribute to the interaction between dystrophin and the C-terminus of dystroglycan: the WW domain (protein–protein interaction domain containing two conserved tryptophan residues), EF hand and ZZ domains [10–12]. The WW domain is the primary site of interaction between dystrophin (or utrophin) and the last C-terminal 15 amino acids of β-dystroglycan [13,14]. The stability of the WW domain and its affinity for β-dystroglycan are greatly increased by the EF hand region which cradles the EF hands of dystrophin in the extracellular domain of dystroglycan [13,14]. The stability of the WW domain and its affinity for β-dystroglycan are greatly increased by the EF hand region which cradles the EF hands of dystrophin in the extracellular domain of dystroglycan [13,14]. The stability of the WW domain and its affinity for β-dystroglycan are greatly increased by the EF hand region which cradles the EF hands of dystrophin in the extracellular domain of dystroglycan [13,14].

**Key words:** Duchenne muscular dystrophy, dystroglycan, dystrophin, epitope mapping, utrophin, zinc binding.
coli BL21(DE3) and purified as described previously [19].

\[ \beta \] mouse [20]. Spleen cells were fused to myeloma to obtain specific injected into mice according to a previously described protocol Diodora aspera to KLH [keyhole-limpet (haemocyanin)] and

The dystrophin ZZ domain sequence (3311–3342) was linked into 10 mM Pipes (pH 7.0) and 1 mM ascorbate with either 1 mM ZnCl₂ or 1 mM phenanthroline. The cytoplasmic domain only of

cytoplasmic domain of dystrophin only of

Point mutations in cysteine residues were generated by overlap extension mutagenesis. The non-fusion protein was expressed in

cultured fibroblasts [18a].

hybridomas and antibodies were selected by ELISA using the antigenic peptide. The dystrophin and utrophin C-terminal polyclonal antibodies (H4 and K7 respectively) were raised in New Zealand rabbits by repeated intradermal injections. Peptides of the last 16 and 11 C-terminal amino acids of dystrophin or utrophin respectively were conjugated via a cysteine residue to KLH and used as antigen. Antibodies were purified and characterized as previously described [21].

**Tissues**

All tissues, muscle, lung and sciatic nerve, were dissected immediately after death and rapidly frozen in 2-methylbutane, cooled in liquid nitrogen and stored at −80°C until use. Crude muscle membrane homogenate was prepared using freshly dissected muscle according to a previous protocol [22].

**ELISA**

ZZ domain sequence synthetic peptide (3311–3342) was coated on microtitre plates at 0.1 mg/ml, and incubated at 4°C overnight in PBS. After washes, the plates were blocked with 0.05 % Tween 20 in PBS buffer containing 1 % (w/v) BSA for 20 min at 37°C, then incubated with each monoclonal antibody for 2 h at 37°C. Reaction was revealed by adding alkaline phosphatase-labelled anti-mouse IgG for 30 min at 37°C and signal was detected at 405 nm using 1 mg/ml p-nitrophenylphosphate (Sigma) in 9.7 % (v/v) diethanolamine buffer (pH 9.8). ELISA assay was performed to test epitope mapping for each monoclonal antibody using the seven-residue synthetic peptides corresponding to the overlapping sequences spanning the D3311–3342 or U3068–3099 ZZ domain. Freshly prepared peptide, 7.7 mg/ml in 0.05 % Tween 20 PBS buffer, was coated on to microtitre plates in triplicate and then incubated with each monoclonal antibody to test their reactivity. For competitive ELISA experiments, microtitre plates were coated in triplicate with peptide 19. After blocking as above, plates were incubated at 4°C overnight with either crude muscle membrane homogenate (0.1 mg/ml), purified β-dystroglycan (9 μg/ml) or with blocking buffer. Monoclonal antibody (13D2) and the commercial β-dystroglycan antibody (1:500, 43DAG/8DS; Novocastra) were added successively. Reactions were revealed as described above.

**Immunofluorescence**

Cryostat sections (10 μm) of unfixed muscle [rabbit and Torpedo marmorata (marbled electric ray)] were labelled with the antibodies described above. Immunoreactivity was detected with Cy3-conjugated sheep anti-mouse IgG (Euromedex).

**Western blotting**

Fresh extracts were prepared from 0.01 g of muscle tissue homogenized in 150 μl of 5 % SDS buffer (50 mM Tris/HCl, pH 8.0, and 10 mM EDTA) supplemented with 1 % trypsin inhibitor and 1 % saponin. After centrifugation (10 min at 13,000 g), supernatant protein concentrations were estimated using the BCA (bicinchoninic acid) protein assay (Pierce). Samples were separated in duplicate by SDS/PAGE (3–10 or 5–15 % gel), transferred to nitrocellulose and developed with appropriate antibody, essentially as described previously [13]. All monoclonal antibodies were tested in competition with an excess of corresponding synthetic peptides (1 mg of peptide per μg/ml of monoclonal antibody [23]) on both cryostat sections and Western blots. All monoclonal antibodies were completely blocked by their specific peptides (see Figure 4).
Far-Western blotting overlay

Blotted nitrocellulose sheets (0.2 µm) containing total muscle protein extract were blocked for 1 h at room temperature with 10 mM triethanolamine (pH 7.6), 140 mM NaCl, 1 mM CaCl₂, and 1 mM MgCl₂ containing 5% BSA and then pre-incubated with peptide 19 (0.1 mg/ml) in 0.5% BSA containing 1 mM dithiothreitol or 0.5% BSA alone (control) for 24 h. Crude membrane homogenates were applied to the nitrocellulose membrane overnight at 4°C with gentle agitation. Membranes were blocked in Tris buffer containing 0.1% Tween 20 and 3% BSA. After washing, proteins were revealed with dystrophin C-terminal antibody (H4).

ZZ domain zinc binding

CD was carried out on a Jobin Yvon CD6 spectrophotometer using 0.6 ml cuvettes. ZZ domain was analysed in the presence of 1 mM ZnCl₂ or 1 mM 1,10-phenanthroline. Aliquots of similar samples were also subjected to SDS/PAGE in the absence or presence of zinc. AAS (atomic absorption spectroscopy) was performed on a Unicam Solaar 929 spectrometer using ZnCl₂ solutions prepared in the same buffer as the ZZ domain as standards at a wavelength of 213.9 nm with a bandpass of 0.5 nm and taking the average of three readings at 1 s intervals. For metal ion competition assays, 10 µg of purified ZZ was spotted on to nitrocellulose and allowed to air dry. Membranes were probed with ⁶⁵ZnCl₂ as described previously [24] using 200 µM ⁶⁵ZnCl₂ (20 µCi/ml) and an excess of the indicated counter ions. Autoradiographs were quantified by densitometry and data expressed relative to ⁶⁵ZnCl₂ alone = 1.0. A SPOT's peptide array comprising 46 peptides of 20 residues each differing by one amino acid covering the complete utrophin ZZ domain (3049–3114) was synthesized as described previously [13]. ⁶⁵ZnCl₂ binding was performed as described above; a separate control experiment was performed in the presence of excess 10 mM ZnCl₂.

RESULTS

ZZ domain zinc binding

Like other proteins that bind bivalent cations, purified bacterially expressed utrophin ZZ domain showed a small upward mobility-shift on SDS/PAGE when the protein was prepared in the presence of zinc, whereas ZZ domain prepared in the presence of the chelator 1,10-phenanthroline ran slightly faster (Figure 2A, inset). This is indicative of a structural change induced by zinc binding altering the SDS/PAGE mobility, a phenomenon commonly seen in cation-binding proteins, such as calmodulin when subjected to SDS/PAGE in the presence or absence of calcium, see e.g. [25]. A conformational change upon zinc binding was also substantiated by CD. The CD spectrum of ZZ domain in the presence of zinc showed a slightly higher propensity towards helical structure compared with ZZ domain with phenanthroline (Figure 2A). Determination of bivalent cation specificity for the ZZ domain by ⁶⁵Zn-overlay revealed most competition for zinc binding by excess zinc or copper (Figure 2B), which is in keeping with the complexing ability of bivalent cations of the transition metals which generally follow the Irving–Williams series Mn < Fe < Co < Ni < Cu > Zn >> Ca/Mg. A subset of the data in (B) was published previously in brief [44]. (C) Densitometric analysis of the data in (B) and two additional independent experiments, with ⁶⁵ZnCl₂ binding in the presence of the indicated competing bivalent cations represented relative to ⁶⁵ZnCl₂ alone = 1. Results shown are means ± S.E.M. (n = 3).

Figure 2 Zinc binding to the utrophin ZZ domain

(A) CD spectrum of the utrophin ZZ domain in the presence of 1 mM ZnCl₂ (dashed line) or absence of zinc (presence of phenanthroline; solid line) indicating a modest structural change on zinc binding. This is reflected in the slightly altered mobility of the ZZ domain on SDS/PAGE in the presence of ZnCl₂ (inset). (B) Autoradiographs of individual ⁶⁵ZnCl₂ overlays of purified ZZ domain in the absence (top left square) or presence of an excess of the indicated competing bivalent cations. ⁶⁵Zn binding is competed in keeping with the Irving–Williams series Mn < Fe < Co < Ni < Cu > Zn >> Ca/Mg. A subset of the data in (B) was published previously in brief [44]. (C) Densitometric analysis of the data in (B) and two additional independent experiments, with ⁶⁵ZnCl₂ binding in the presence of the indicated competing bivalent cations represented relative to ⁶⁵ZnCl₂ alone = 1. Results shown are means ± S.E.M. (n = 3).

to the suggestion that the ZZ domain might adopt a structure equivalent to half of a LIM (Lin-11, Isl-1, Mec-3) domain [27]. ZZ domains in most other proteins, however, contain six conserved cysteine residues in positions that could co-ordinate zinc with additional histidine and other potential liganding residues (see Figure 8) [12].
**65Zn-overlay assays**

We therefore mutated each of the five cysteine residues in the utrophin ZZ domain and performed 65Zn-overlay assays. No qualitative difference was observed in zinc binding as determined by autoradiography, suggesting that the ZZ domain did not adopt a half LIM domain-like conformation, as removal of any one cysteine should prevent zinc co-ordination. For the constructs where enough soluble material could be produced, we further examined the ZZ domain zinc binding using AAS. The wild-type purified protein, refolded from urea, contained sub-stoichiometric quantities of zinc, 0.65 ± 0.03 mol of Zn/mol of ZZ, suggesting that the protein was not all correctly folded. However, the zinc content of the utrophin ZZ domain mutant C3071A appeared stoichiometric at 2.14 ± 0.1 mol of Zn/mol of ZZ: thus two, rather than one, zinc ions bound to the ZZ domain. We hypothesize that the mutation of Cys3071 to alanine removed a ‘free’ unco-ordinated cysteine residue that led to inappropriate zinc co-ordination, possible disulfide formation and aggregation of the domain leading to insolubility. To confirm the stoichiometry of zinc binding determined by AAS, we used a peptide SPOTs array of 20-amino-acid peptides each differing from the previous by one amino acid spanning the 66 residues of the ZZ domain to examine 65Zn binding. As shown in Figure 3(A), two distinct regions of the utrophin ZZ domain bound zinc, in part corroborating the AAS data. Zinc is typically co-ordinated by cysteine and histidine residues, but aspartic acid and glutamic acid residues are also able to act as ligands with water contributing in catalytic situations [28]. The first zinc-binding region, peptides 6–16, contained a glutamic acid residue, a histidine residue, two of the conserved cysteine residues and a further cysteine residue unique to dystrophin and utrophin. Each potential liganding residue was separated by two residues which could theoretically accommodate the co-ordination of a zinc ion (Figure 3A). The other region, peptides 30–37, contained the second pair of conserved cysteines, a histidine and an aspartic acid (Figure 3A). Rather than a zinc finger, the ZZ domain may therefore contain two zinc ‘knuckles’ as depicted in Figure 3(B), although other conformations are possible. The binding of zinc to the peptide regions described above must rely on some local sequence specificity and not the simple presence of potential co-ordinating ligands, as peptides 43–46, which all contain a pair of histidines and a pair of cysteines in a configuration one might expect to be able bind zinc, showed no labelling with 65Zn (Figure 3A). The synthesis of SPOTs peptides is not quantitative; therefore strength of binding interaction cannot necessarily be inferred from the intensity in any one SPOT as the quantities of peptide in each SPOT may differ. However, the presence of radioactivity of broadly similar intensity across several SPOTs is likely to indicate a similar affinity for the ligand over those SPOTs.

**Monoclonal antibody selection and epitope mapping**

Monoclonal antibodies directed towards the ZZ domain of dystrophin (3311–3342) were collected as hybrid supernatants, selected by ELISA using recombinant ZZ domain and named 13D2, 12D7, 14A4 and 4G3. Specificity and epitope mapping was performed for the four selected supernatants by ELISA against the series of seven-residue peptides from the dystrophin ZZ domain (Figure 1A) including those common to dystrophin and utrophin. A specific response is obtained with peptide 19 (D3326–3332/U3081–3087) for 13D2 supernatant, with peptide 1 (D3315–3331/U3072–3078) for 12D7 supernatant and with peptide 33 (D3335–3341) for 14A4 supernatant, while no specific response was obtained with supernatant 4G3 (Figure 4A). Peptide 33 is unique to dystrophin as it contains one of the isoleucines that is replaced by valine in the utrophin ZZ domain. We therefore re-screened serum 14A4 hybrid supernatant against all peptides that spanned the equivalent region in dystrophin and utrophin but, as shown in Figure 4(B), supernatant 14A4 was specific for peptide 33 and did not recognize the equivalent peptide from utrophin with an isoleucine to valine substitution (peptide 34). The respective epitopes of the selected antibodies are presented schematically in Figure 4(C) taking into account the topological information derived from Figure 3.

**Immunodetection of the dystrophin ZZ domain**

The four monoclonal antibodies were tested by immunofluorescence detection using both *T. marmorata* and rabbit muscle (Figures 5A and 5B). Serum 13D2 shows no specific sarcolemmal labelling, whereas both 12D7 and 14A4 antibodies produced the expected sarcolemmal labelling typical of dystrophin staining in skeletal muscle. Specific staining was blocked by pre-incubation of the hybrid supernatant with the respective peptide. The 4G3 antibody, which did not detect any specific dystrophin or utrophin ZZ domain peptide, produced a labelling pattern only in the cytoplasmic compartment of muscle fibres. These antibodies
were further tested by Western blot on total protein homogenates from rabbit skeletal muscle (Figure 5C) or *T. marmorata* (results not shown). In keeping with the immunofluorescence detection pattern in muscle sections, no protein band was detected using the 13D2 antibody, while a 400 kDa protein band, corresponding to the expected molecular mass of dystrophin, was obtained by 12D7 and 14A4 antibodies (Figure 5). Specific staining was again blocked by pre-incubation of the serum with the respective peptide. Using protein extract from dystrophin-deficient mdx mouse muscle (Figure 5D), 12D7 and 14A4 antibodies fail to give a 400 kDa protein band, indicating that these antibodies recognize specifically the dystrophin ZZ domain sequence. The 4G3 monoclonal antibody revealed an unknown protein band with molecular mass of approx. 170 kDa. Monoclonal supernatant 13D2 specifically recognized peptide 19 common to the dystrophin/utrophin ZZ domain (Figure 4A). It is surprising therefore that it did not recognize dystrophin in tissue sections or on Western blots (Figures 5A and 5B). This lack of reactivity might imply that the epitope for 13D2 is masked in tissue sections or is dependent on conformation; the latter might also explain its lack of reactivity in Western blots.

**ELISA competition assays**

In order to further investigate the reasons behind this lack of reactivity, we performed competitive ELISA experiments in microtitre plates coated with peptide 19. In two separate experiments we examined the competition between purified β-dystroglycan or a skeletal-muscle membrane fraction enriched for β-dystroglycan, and the 13D2 ZZ domain antibody or 43DAG/8D5, a monoclonal hybrid supernatant against β-dystroglycan. All experiments, including controls, were carried out
in the presence of 1% BSA. The two experiments produced qualitatively similar results (Figure 6). 13D2 incubation produced a consistent high signal across all wells (Figure 6), consistent with the specificity of this monoclonal antibody for peptide 19 (Figure 4). The monoclonal antibody 43DAG/8D5 against β-dystroglycan, however, gave a consistent low signal across all wells, demonstrating that, like the related antiserum MANDAG2 (mouse anti-β-dystroglycan 2), this hybridoma supernatant does not recognize peptide 19 and is specific for the WW domain interaction sequence and PPPYVP epitope at the C-terminus of β-dystroglycan (Supplementary Figure 1 at http://www.BiochemJ.org/bj/401/bj4010667add.htm) and as reported previously [13,29]. Increasing concentrations of either purified recombinant β-dystroglycan (Figure 6A) or dystroglycan-containing membrane fraction (Figure 6B), competed for 13D2 binding to peptide 19 reducing the signal from successive wells. Conversely the detection of β-dystroglycan with 43DAG/8D5 revealed an increase in β-dystroglycan binding to peptide 19 with increasing β-dystroglycan or dystroglycan-containing membrane fraction competition across successive wells. Thus peptide 19 appears to be able to bind β-dystroglycan which can compete specifically for the 13D2 monoclonal antibody, suggesting that the region of the dystrophin and utrophin ZZ domains, corresponding to peptide 19, is an additional binding site for β-dystroglycan on dystrophin and utrophin. Furthermore, the ability of 43DAG/8D5 to still recognize β-dystroglycan bound to peptide 19 suggests that the two binding events are independent in this context.

Far-Western blotting of β-dystroglycan with dystrophin and utrophin ZZ domains

Total mouse muscle extract transferred to nitrocellulose was overlaid with a dystrophin-enriched crude membrane homogenate of mouse skeletal muscle, or with a utrophin-enriched crude membrane homogenate of mdx mouse skeletal muscle or sciatic nerve. The dystrophin in the enriched dystrophin homogenate bound to β-dystroglycan on the nitrocellulose membrane as revealed by blotting for the dystrophin C-terminus (Figure 7A3; Pep19–). When the blot was pre-incubated with peptide 19, however, the binding of dystrophin in the membrane homogenate to dystroglycan on the blot was strongly reduced (Figure 7A3; Pep19+). This result demonstrates that the peptide 19 can effectively block dystrophin binding to intact β-dystroglycan, again highlighting the importance of the ZZ domain for the dystrophin–dystroglycan interaction. In a similar experiment overlaying an enriched utrophin homogenate from dystrophin-deficient mdx mouse or sciatic nerve, utrophin detection using the C-terminal utrophin antibody (K7) showed that the fraction of utrophin that bound β-dystroglycan was less compared with that observed with dystrophin, suggesting that utrophin has a
lower affinity for β-dystroglycan (Figure 7B3; Pep19–). However, when peptide 19 was applied, there was still a slight reduction in utrophin binding (Figure 7B3; Pep19 +). The apparent difference in inhibition of binding to β-dystroglycan is not likely to be due to the slightly lower dystrophin + utrophin content seen in the mdx mice samples, compare quantifications in Figures 7(A4) and 7(B4). The difference in competition for β-dystroglycan binding probably reflects a real difference in the mode of binding between the dystrophin or utrophin ZZ domain, and β-dystroglycan. This may be due to other DGC (dystrophin–glycoprotein complex) components assembling differently in the mdx mouse in the presence of utrophin, which contributes to a slightly different mode of interaction with dystroglycan.

**DISCUSSION**

The ZZ domain

ZZ domains are a highly conserved and widespread zinc-binding motif first identified in dystrophin/utrophin and the transcriptional co-activator CBP [CREB (cAMP-response-element-binding protein)-binding protein]/p300 [12] (Figure 8). In dystrophin, the first half of the C-terminal domain and ZZ-domain-containing cysteine-rich region has been implicated in binding to β-dystroglycan, and when mutated gives rise to a severe muscle-wasting phenotype [2,30,31]. This region contains several modular protein domains: a WW domain, two incomplete but putative calcium-binding sites (EF hands) [32] and a ZZ domain (zinc finger domain) [12]. An examination of the spectrum of point mutations in the human dystrophin gene in the ZZ domain region (Table 1) reveals that four of these mutations, where a full-length protein product may be produced, are in zinc-liganding residues implicated in our studies. The missense mutation C3313F produced a DMD phenotype, although no information is available as to whether this individual had any dystrophin protein expression [33]. D3335H on the other hand was identified in an individual with a normal level of correctly localized full-length dystrophin and dystrophin-associated proteins, but yet a severe DMD phenotype [34]. From our analysis of 65Zn peptide SPOTs overlay, D3335 is a potential liganding residue (Figure 3), but mutation of this residue to histidine in biochemical experiments had no effect on β-dystroglycan binding [35]. Although aspartic acid to histidine substitution is not normally considered a conservative substitution, in this context histidine could replace aspartic acid and still co-ordinate zinc, thus preserving protein conformation and, as suggested from the patient phenotype, presumably some function too. It may be that Asp3335 has another important functional role that so far has not been elucidated and that is not supported by a histidine substitution, but it is difficult to predict what that might be. Aspartic acid in this position is conserved in most ZZ domain sequences (Figure 8), suggesting a functional importance [12].
Figure 7 Overlay experiments using electroblotted total crude muscle membrane homogenate (Ht)

(A1) and (A2) correspond to the native nitrocellulose with total electrotransferred Ht revealed by LG5 and H4 polyclonal antibodies (anti-β-dystroglycan and anti-dystrophin respectively). Membranes were overlaid with enriched dystrophin homogenate comprising dystrophin and its associated proteins. Detection was performed with a dystrophin C-terminal antibody (H4). When peptide 19 was pre-incubated before overlay with the dystrophin-enriched homogenate, only a 400 kDa band was detected with H4 polyclonal antibody, suggesting that the binding site for β-dystroglycan was blocked (A3). Panel (B) represents the same overlay experiment performed with utrophin-enriched homogenate from mdx mouse comprising utrophin and its associated proteins detected by the C-terminal β-dystroglycan and utrophin antibodies (B1 and B2 respectively). Panel (B3) showed that the utrophin-binding properties for β-dystroglycan are slightly different from those of dystrophin and were not reduced to the same extent when peptide 19 was applied. Panels (A4) and (B4) represent densitometric quantification of the amounts of dystrophin (DYS) and utrophin (UTR) present in the two fractions.

Zinc binding

An NMR structure of the ZZ domain from CBP revealed a cross-brace zinc finger motif [36], where the individual zinc ions are co-ordinated by non-linear sequence elements, with the protein backbone crossing back on itself to form a zinc-binding site (Figure 8B). The SPOTs analysis carried out in Figure 3 could not reveal co-ordination of zinc through such a structure as the individual peptides were only 20 amino acids long, and from the CBP ZZ domain structure the liganding residues are 21 and 26 residues apart in the linear sequence [36]. Due to insertions in the dystrophin/utrophin sequences, this corresponds to 27 and 28 residues apart in the linear sequence [36]. Due to insertions in the dystrophin/utrophin sequences, this corresponds to 27 and 28 residues apart, too long to provide an unambiguous interpretation in the peptide array. But, as highlighted in Figure 3, it does not appear that just any combination of four residues that could co-ordinate zinc will bind zinc. The two pairs of cysteine and histidine residues in peptides 43–46 of the SPOTs are appropriately spaced to bind zinc (Figure 3A) but do not, suggesting a degree of specificity to the other sequences identified by this method that do bind zinc. Moreover, unlike almost all other ZZ domain sequences in the databases, vertebrate dystrophin and utrophin lack three of the conserved residues that form the second zinc-binding site in the CBP ZZ domain: the central pair of cysteines and one of the C-terminal histidines (Figure 8B) [12,36]. This would suggest that dystrophin and utrophin bind zinc in a different conformation and this conformation may be specific to the ability of these proteins to interact with dystroglycan through multiple modes of interaction as discussed below. Interestingly the vertebrate dystrobrevins and invertebrate dystrophins and dystrobrevins do have cysteine residues in these positions, suggesting some functional divergence with the emergence of distinct dystrophin and utrophin genes in vertebrates.

Dystroglycan binding: role of the WW domain

We and others have independently mapped the site for dystrophin and utrophin binding to dystroglycan to the last 15 amino acids at the C-terminus of β-dystroglycan [13,14,16,37–39]. The major
The deletion of a conserved Glu3367 just C-terminal of the ZZ domain resulted in a DMD phenotype frameshift and/or truncation rather than any specific point mutation. A rare single amino acid downstream of the point mutation. Consequently, the DMD phenotypes could be due to the DMD

DMD AKCNICKECPIIGFRYRSLKHFNYDICL
H
DMD AKCNICKECPIIGFRYRSLKHFNY
Despite normal correctly localized protein [47].

Table 1 Missense mutations in the ZZ domain of dystrophin

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Dystrophin ZZ domain</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type</td>
<td>A$^{311}$KCNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[33]</td>
</tr>
<tr>
<td>DMD</td>
<td>AK$^{311}$CNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[34]</td>
</tr>
<tr>
<td>BMD</td>
<td>AK$^{311}$CNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[45]</td>
</tr>
<tr>
<td>DMD</td>
<td>AK$^{311}$CNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[45]</td>
</tr>
<tr>
<td>DMD$^*$</td>
<td>AK$^{311}$CNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[46]</td>
</tr>
<tr>
<td>DMD$^+$</td>
<td>AK$^{311}$CNICKEPIGFRYRSLKHFNYDICOOSCF</td>
<td>[46]</td>
</tr>
</tbody>
</table>

*† These mutations produced frameshifting stop codons 34 (†) and 8 (†) codons respectively downstream of the point mutation. Consequently, the DMD phenotypes could be due to the frameshift and/or truncation rather than any specific point mutation. A rare single amino acid deletion of a conserved Glu$^{357}$ just C-terminal of the ZZ domain resulted in a DMD phenotype despite normal correctly localized protein [47].

Dystroglycan binding: role of the ZZ domain

Detailed biochemical analyses have pointed to a role for the ZZ domain in further supporting and contributing to this binding interface [16,35]. Moreover, Rentschler et al. [16] even go so far as to suggest that there is an additional binding site between dystroglycan and non-WW domain regions in dystrophin, possibly the ZZ domain. Transgenic mdx mice expressing various dystrophin gene constructs showed that the dystrophic change in mdx muscle could be rescued [41,42]. Because the binding of dystrophin to β-dystroglycan is required to prevent the dystrophic phenotype, deletion models can be considered to exhibit effective and physiologic binding activity in these mice. In this context, the full-length cDNA with deletion of exons 68–70 (ZZ domain) failed to rescue the phenotype [41] despite the presence of the WW–EF region. Another model with deletion of exons 64–67 (EF hands) also failed to rescue the phenotype [42]. This model, which includes the WW domain encoded by exons 62–63 but lacks the subsequent EF1 and EF2, suggests as in the biochemical experiments that the WW domain alone is not sufficient for effective binding to β-dystroglycan. On the other hand, a mouse with deletion of exons 71–78 could rescue the phenotype, suggesting that the C-terminal region encoded by these exons is not essential for the binding [42]. All these results are compatible with the fact that the C-terminal region of dystrophin spanning 3311–3342, the ZZ domain, is crucial for binding to β-dystroglycan. Our results suggest that we could limit the direct binding activity of this crucial region to the residues D3326–3332.

© 2007 Biochemical Society
or U3083–3089 of dystrophin or utrophin respectively (peptide 19). Taken together, these results are consistent with there being a second dystroglycan-binding site between dystrophin/utrophin ZZ domain and dystroglycan in addition to the WW domain-mediated interaction with the extreme C-terminus of β-dystroglycan. As shown in Figure 6, this region is likely to be distinct from the well-characterized PPPYYP site due to the inability of 43DAG/8D5 to compete for peptide 19 binding to purified β-dystroglycan. This additional binding site further stabilizes the β-dystroglycan–WW domain interaction, which itself is supported by the EF hand region, and explains why the complete WW–EF–ZZ region appears to be required for full binding activity between β-dystroglycan and dystrophin or utrophin.

ZZ domain mutations in humans

The first missense mutation reported in the C-terminal region was C3340Y from a patient with DMD and mental retardation, but with approx. 20% of normal levels of dystrophin immunoreactivity and some β-dystroglycan staining at the sarcolemma [43]. From our analyses, Cys3573→Ser would be predicted to be essential for the formation of the second zinc knuckle (Figure 3), and mutation to tyrosine would ablate the zinc-binding site. Biochemical analysis of this mutation, and also an engineered C3340S substitution, in the context of the interaction between dystrophin and β-dystroglycan also demonstrates a loss of function [35] in support of the patient data and our own analysis of the zinc-binding site. From the biochemical analysis of mutations of all the cysteines in the dystrophin ZZ domain, only C3340Y prevents dystroglycan binding. Mutations C3313Y, C3316Y and C3319Y still allow 43DAG/8D5 to compete for peptide 19 binding to purified β-dystroglycan from the well-characterized PPPYVP site due to the inability of glycan. As shown in Figure 6, this region is likely to be distinct on the ZZ domain, and highlight distinct differences in the mode of interaction between β-dystroglycan and the dystrophin or utrophin ZZ domains.

Summary

The above data provide a conceptual advance on previously reported findings [16,35] and define the ZZ domain in concert with the WW domain as being a crucial structural and functional part of the dystrophin/utrophin–β-dystroglycan interaction that is involved in anchoring these proteins to the cell membrane. The identification of the short dystrophin peptide YRSLKHIF defines a second β-dystroglycan-binding site in dystrophin and utrophin and raises the possibility of identifying further specific antibodies that could be used to distinguish between dystrophin and utrophin in this highly similar region. Finally, biochemical approaches, epitope mapping, ELISA and overlay provide new evidence for the zinc-binding properties and β-dystroglycan interaction site on the ZZ domain, and highlight distinct differences in the mode of interaction between β-dystroglycan and the dystrophin or utrophin ZZ domains.

K. Hnia was supported by the AFM (Association Francaise contre les Myopathies; Fellowship no. 10529), D. M. by Montpellier 1 University and CNRS (Centre National de la Recherche Scientifique), and S. J. W. by the BBSRC (Biotechnology and Biological Sciences Research Council; ICR07596), MRC (G0001004) and Wellcome Trust (042180). We are extremely grateful to Jurgen Wehland (Department of Cell Biology, Heimholtz Centre for Infection Research, Braunschweig, Germany) for synthesis of the ZZ domain peptide SPOT array and to Louise Anderson, who sadly and prematurely passed away in 2005, for generous supplies of 43DAG/8D5.

REFERENCES


Received 12 July 2006/29 September 2006; accepted 29 September 2006
Published as BJ Immediate Publication 29 September 2006, doi:10.1042/BJ20061051

© 2007 Biochemical Society